Cognition Therapeutics Inc.
CGTX
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$16M
▲ +30.9% YoY
Op. Margin
–
ROIC
-92.77%
▲ +51.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$15M
▲ +13.7% YoY
Op. Cash Flow (TTM)
-$15M
▲ +13.6% YoY
Net Debt
-$30M
Net Cash Position
Cash & Equiv.
$31M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CGTX
Held by ETFs
CGTX is in 2 US ETFs. The largest of them, with CGTX's weight in each:
Cognition Therapeutics (CGTX) in two numbers
Questions about Cognition Therapeutics
Does Cognition Therapeutics (CGTX) pay a dividend?
No. Cognition Therapeutics (CGTX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 2 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in CGTX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CGTX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.